Quantitative and ultrasensitive in situ immunoassay technology for SARS-CoV-2 detection in saliva

Yuchao Chen, Fei Liu, Luke P. Lee

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


The coronavirus disease 2019 (COVID-19) pandemic has become an immense global health crisis. However, the lack of efficient and sensitive on-site testing methods limits early detection for timely isolation and intervention. Here, we present a quantitative and ultrasensitive in situ immunoassay technology for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection in saliva (QUIT SARS-CoV-2). Our nanoporous membrane resonator generates a rapid oscillating flow to purify and concentrate fully intact SARS-CoV-2 virus in saliva by 40-fold for in situ detection of viral antigens based on chemiluminescent immunoassay within 20 min. This method can not only achieve a detection sensitivity below 100 copies/ml of virus, comparable to the bench-top PCR equipment; it can also improve detection specificity via direct monitoring of viral loads. The integrated portable QUIT SARS-CoV-2 system, which enables rapid and accurate on-site viral screening with a high-throughput sample pooling strategy, can be performed in primary care settings and substantially improve the detection and prevention of COVID-19.

Original languageEnglish
Article numbereabn3481
JournalScience Advances
Issue number21
StatePublished - May 2022

Bibliographical note

Publisher Copyright:
Copyright © 2022 The Authors, some rights reserved.


Dive into the research topics of 'Quantitative and ultrasensitive in situ immunoassay technology for SARS-CoV-2 detection in saliva'. Together they form a unique fingerprint.

Cite this